| List of Cases |
International
Business (English Language) 3k. |
|
|
|
Presentations
submission timeliness, slide quality, oratorical art, audience involvement in
the case study 0-3 |
The complexity of
the analyzed problem 0-3 |
Case studies
breadth, i.e. quite a lot of work done 0-4 |
Depth of the case
analysis, i.e. use sophisticated analytical techniques 0-4 |
It was collected an
additional, interesting and valuable material on the Internet 0-2 |
A summary of the
findings, what is memorable, the most valuable of the case presented, where
you can apply the acquired knowledge 0-2 |
Working as opponent of the peer
presentations or active participation in the cases analysis 0-1. Good questions or comments prized pluses,
3-4 pluses equal to 1 point. |
|
|
|
|
|
|
|
|
|
|
| # |
Page |
Case |
The names
of students who analyzed the case |
Date of
presentation |
Presentations
queue |
Slides of
the presentation |
Additional
material 1 |
Additional
material 2 |
Assessment
of case study |
| 1 |
365-369 |
Valuing Capital investment Projects |
ziyan Tian, |
|
3 |
|
|
|
9 |
3 |
2 |
1 |
|
1 |
2 |
|
| |
365-369 |
Valuing Capital investment Projects |
Mykolas Baranauskas |
|
3 |
|
|
|
9 |
3 |
2 |
1 |
|
1 |
2 |
|
| 2 |
365-369 |
Valuing Capital investment Projects |
Issel Davide |
|
3 |
|
|
|
9 |
3 |
2 |
1 |
|
1 |
2 |
|
| 3 |
371-376 |
Merck & Company: Evaluating a Drug Licensing Opportunity |
Sergey Yuriev |
|
8 |
|
|
|
6 |
2 |
2 |
1 |
|
|
1 |
|
| 4 |
371-376 |
Merck & Company: Evaluating a Drug Licensing Opportunity |
Hlib Krapyvko |
|
8 |
|
|
|
6 |
2 |
2 |
1 |
|
|
1 |
|
| |
371-376 |
Merck & Company: Evaluating a Drug Licensing Opportunity |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 5 |
377-379 |
Tree Values |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 6 |
377-379 |
Tree Values |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| |
377-379 |
Tree Values |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 7 |
381-394 |
The Super Project |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 8 |
381-394 |
The Super project |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| |
381-394 |
The Super project |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 9 |
395-403 |
Net Flix |
Domas
Cerniauskis |
|
1 |
|
|
|
10 |
3 |
2 |
2 |
|
1 |
1 |
1 |
| 10 |
395-403 |
Net Flix |
Mukhammad
Khalili |
|
1 |
|
|
|
10 |
3 |
2 |
2 |
|
1 |
1 |
1 |
| |
395-403 |
Net Flix |
Ugnė Maldeikytė |
|
1 |
|
|
|
9 |
3 |
2 |
2 |
|
1 |
1 |
|
| |
395-403 |
Net Flix |
Karina Kribs |
|
1 |
|
|
|
10 |
3 |
2 |
2 |
|
1 |
1 |
1 |
| |
395-403 |
Net Flix |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 11 |
405-418 |
A-Rod: Signing the Best Player in Baseball |
Manuel Urda
Rodriguez |
|
7 |
|
|
|
9 |
3 |
2 |
2 |
1 |
|
1 |
|
| |
405-418 |
A-Rod: Signing the Best Player in Baseball |
|
|
7 |
|
|
|
0 |
|
|
|
|
|
|
|
| |
405-418 |
A-Rod: Signing the Best Player in Baseball |
|
|
7 |
|
|
|
0 |
|
|
|
|
|
|
|
| 12 |
405-418 |
A-Rod: Signing the Best Player in Baseball |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| |
405-418 |
A-Rod: Signing the Best Player in Baseball |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 13 |
419-423 |
Ocean Carriers |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 14 |
419-423 |
Ocean Carriers |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| |
419-423 |
Ocean Carriers |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 15 |
405-418 |
Whirlpool Europe |
Gabija Jutelytė |
|
4 |
|
|
|
8 |
3 |
2 |
1 |
|
1 |
1 |
|
| 16 |
405-418 |
Whirlpool Europe |
Augustė Nausėdaitė |
|
4 |
|
|
|
9 |
3 |
2 |
1 |
|
1 |
1 |
1 |
| |
405-418 |
Whirlpool Europe |
Paulina Tarnauskaitė |
|
4 |
|
|
|
8 |
3 |
2 |
1 |
|
1 |
1 |
|
| |
405-418 |
Whirlpool Europe |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 17 |
431-434 |
Health Development Corporation |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 18 |
431-435 |
Health Development Corporation |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 19 |
431-436 |
Health Development Corporation |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 20 |
431-437 |
Health Development Corporation |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 21 |
431-438 |
Health Development Corporation |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 22 |
431-439 |
Health Development Corporation |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 23 |
431-440 |
Health Development Corporation |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 24 |
431-441 |
Health Development Corporation |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 25 |
431-442 |
Health Development Corporation |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 18 |
431-443 |
Health Development Corporation |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 19 |
257 |
The Investment Detective
(Investment criteria and discounted cash flow) |
Buhagiar Gabriel |
|
|
|
|
|
10 |
3 |
2 |
2 |
|
1 |
1 |
1 |
| 20 |
257 |
The Investment Detective
(Investment criteria and discounted cash flow) |
Anne-Laure Charrel-Martin |
|
|
|
|
|
9 |
3 |
2 |
2 |
|
1 |
1 |
|
| 21 |
257 |
The Investment Detective
(Investment criteria and discounted cash flow) |
Antoine Rival |
|
|
|
|
|
9 |
3 |
2 |
2 |
|
1 |
1 |
|
| |
257 |
The Investment Detective
(Investment criteria and discounted cash flow) |
Solene Bluteau |
|
|
|
|
|
9 |
3 |
2 |
2 |
|
1 |
1 |
|
| 22 |
259 |
Worldwide Paper Company
(Analysis of an expansion investment) |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 23 |
259 |
Worldwide Paper Company
(Analysis of an expansion investment) |
Ricardo Guerrero |
|
9 |
|
|
|
0 |
|
|
|
|
|
|
|
| 24 |
259 |
Worldwide Paper Company
(Analysis of an expansion investment) |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 25 |
263 |
Target Corporation
(Multifaceted capital investment decisions) |
Aleksandra Poltoržickaja |
|
5 |
|
|
|
7 |
1 |
2 |
2 |
|
1 |
1 |
|
| 26 |
263 |
Target Corporation
(Multifaceted capital investment decisions) |
Irina Žigaitė |
|
5 |
|
|
|
9 |
2 |
2 |
2 |
|
1 |
1 |
1 |
| 27 |
263 |
Target Corporation
(Multifaceted capital investment decisions) |
Anastasia Jakutytė |
|
5 |
|
|
|
9 |
3 |
2 |
2 |
|
1 |
1 |
|
| 28 |
283 |
Aurora Textile Company
(Analysis of an automation investment) |
Viktorija Kopūstaitė |
|
10 |
|
|
|
0 |
|
|
|
|
|
|
|
| 29 |
283 |
Aurora Textile Company
(Analysis of an automation investment) |
Tadas Baltaduonis |
|
10 |
|
|
|
0 |
|
|
|
|
|
|
|
| 30 |
283 |
Aurora Textile Company
(Analysis of an automation investment) |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 31 |
295 |
Compass Records (Analysis
of working capital investment) |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 32 |
295 |
Compass Records (Analysis
of working capital investment) |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 33 |
295 |
Compass Records (Analysis
of working capital investment) |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 34 |
309 |
Victoria Chemicals plc (A): The Merseyside Project (Relevant cash flows) |
Magdalena Žukovska |
|
2 |
|
|
|
8 |
3 |
2 |
1 |
|
1 |
1 |
|
| 35 |
309 |
Victoria Chemicals plc (A): The Merseyside Project (Relevant cash flows) |
Martyna Rudzionyte |
|
2 |
|
|
|
8 |
3 |
2 |
1 |
|
1 |
1 |
|
| 36 |
309 |
Victoria Chemicals plc (A): The Merseyside Project (Relevant cash flows) |
Mirena Stasilo |
|
2 |
|
|
|
9 |
3 |
2 |
1 |
|
1 |
1 |
1 |
| 37 |
317 |
Victoria Chemicals plc (B): Merseyside and Rotterdam
Projects (Mutually exclusive
investment opportunities) |
Viktorija Brazaite |
|
2 |
|
|
|
8 |
3 |
2 |
1 |
|
1 |
1 |
|
| 38 |
317 |
Victoria Chemicals plc (B): Merseyside and Rotterdam
Projects (Mutually exclusive
investment opportunities) |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 39 |
317 |
Victoria Chemicals plc (B): Merseyside and Rotterdam
Projects (Mutually exclusive
investment opportunities) |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 40 |
325 |
Euroland Foods S.A.
(Strategic resource allocation) |
Javier Sierra Gil |
|
6 |
|
|
|
7 |
3 |
2 |
1 |
|
|
1 |
|
| 41 |
325 |
Euroland Foods S.A.
(Strategic resource allocation) |
Jesus
Gonzalez Suarez |
|
6 |
|
|
|
7 |
3 |
2 |
1 |
|
|
1 |
|
| 42 |
325 |
Euroland Foods S.A.
(Strategic resource allocation) |
Alvaro Pajares Camacho |
|
6 |
|
|
|
7 |
3 |
2 |
1 |
|
|
1 |
|
| |
325 |
Euroland Foods S.A.
(Strategic resource allocation) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 43 |
337 |
Star River Electronics Ltd.(Capital project analysis and
forecasting) |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 44 |
337 |
Star River Electronics Ltd.(Capital project analysis and
forecasting) |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 45 |
337 |
Star River Electronics Ltd.(Capital project analysis and
forecasting) |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 46 |
|
|
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 47 |
|
|
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
| 48 |
|
|
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|